Literature DB >> 18448175

Cytotoxic interactions of methylene blue with trypanosomatid-specific disulfide reductases and their dithiol products.

Kathrin Buchholz1, Marcelo A Comini, Dirk Wissenbach, R Heiner Schirmer, R Luise Krauth-Siegel, Stephan Gromer.   

Abstract

Methylene blue (MB) is known to have trypanocidal activity. We tested the interactions of MB with a number of trypanosomatid-specific molecules of the antioxidant metabolism. At pH 7, trypanothione and other (di)thiols were oxidized to disulfides by the phenothiazine drug. MB inhibited Trypanosoma cruzi trypanothione reductase (TR) (K(i)=1.9 microM), and served as a significant subversive substrate of this enzyme (K(M)=30 microM, k(cat)=4.9s(-1)). With lipoamide dehydrogenase, the second thiol-generating flavoenzyme of T. cruzi, the catalytic efficiency for MB reduction was found to be almost 10(6)M(-1)s(-1). When the system MB-enzyme-molecular oxygen acts as a NAD(P)H-driven redox cycler, a reactive oxygen species, H(2)O(2) or superoxide, is produced in each cycle. Since MB is an affordable, available, and accessible drug it might be tested--alone or in drug combinations--against trypanosomatid-caused diseases of animal and man.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448175     DOI: 10.1016/j.molbiopara.2008.03.006

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  2 in total

1.  Anti-Trypanosoma cruzi effect of the photodynamic antiparasitic chemotherapy using phenothiazine derivatives as photosensitizers.

Authors:  Artur F S Barbosa; Ivanilson P Santos; Gustavo M P Santos; Tanira M Bastos; Vinícius P C Rocha; Cássio S Meira; Milena B P Soares; Ivan R Pitta; Antônio Luiz Barbosa Pinheiro
Journal:  Lasers Med Sci       Date:  2019-05-12       Impact factor: 3.161

Review 2.  1,4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents.

Authors:  Didier Belorgey; Don Antoine Lanfranchi; Elisabeth Davioud-Charvet
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.